Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor - PubMed (original) (raw)
. 2001 Apr 27;276(17):14153-60.
doi: 10.1074/jbc.M010429200. Epub 2001 Jan 11.
Affiliations
- PMID: 11154697
- DOI: 10.1074/jbc.M010429200
Free article
Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor
L O Gerlach et al. J Biol Chem. 2001.
Free article
Abstract
The non-peptide CXCR4 receptor antagonist AMD3100, which is a potent blocker of human immunodeficiency virus cell entry, is a symmetrical bicyclam composed of two identical 1,4,8,11-tetraazacyclotetradecane (cyclam) moieties connected by a relatively rigid phenylenebismethylene linker. Based on the known strong propensity of the cyclam moiety to bind carboxylic acid groups, receptor mutagenesis identified Asp(171) and Asp(262), located in transmembrane domain (TM) IV and TM-VI, respectively, at each end of the main ligand-binding crevice of the CXCR4 receptor, as being essential for the ability of AMD3100 to block the binding of the chemokine ligand stromal cell-derived factor (SDF)-1alpha as well as the binding of the receptor antibody 12G5. The free cyclam moiety had no effect on 12G5 binding, but blocked SDF-1alpha binding with an affinity of 3 microm through interaction with Asp(171). The effect on SDF-1alpha binding of a series of bicyclam analogs with variable chemical linkers was found to rely either only on Asp(171), i.e. the bicyclams acted as the isolated cyclam, or on both Asp(171) and Asp(262), i.e. they acted as AMD3100, depending on the length and the chemical nature of the linker between the two cyclam moieties. A positive correlation was found between the dependence of these compounds on Asp(262) for binding and their potency as anti-human immunodeficiency virus agents. It is concluded that AMD3100 acts on the CXCR4 receptor through binding to Asp(171) in TM-IV and Asp(262) in TM-VI with each of its cyclam moieties, and it is suggested that part of its function is associated with a conformational constraint imposed upon the receptor by the connecting phenylenebismethylene linker.
Similar articles
- Metal ion enhanced binding of AMD3100 to Asp262 in the CXCR4 receptor.
Gerlach LO, Jakobsen JS, Jensen KP, Rosenkilde MR, Skerlj RT, Ryde U, Bridger GJ, Schwartz TW. Gerlach LO, et al. Biochemistry. 2003 Jan 28;42(3):710-7. doi: 10.1021/bi0264770. Biochemistry. 2003. PMID: 12534283 - Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
Rosenkilde MM, Gerlach LO, Hatse S, Skerlj RT, Schols D, Bridger GJ, Schwartz TW. Rosenkilde MM, et al. J Biol Chem. 2007 Sep 14;282(37):27354-27365. doi: 10.1074/jbc.M704739200. Epub 2007 Jun 28. J Biol Chem. 2007. PMID: 17599916 - Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100.
Hatse S, Princen K, Gerlach LO, Bridger G, Henson G, De Clercq E, Schwartz TW, Schols D. Hatse S, et al. Mol Pharmacol. 2001 Jul;60(1):164-73. doi: 10.1124/mol.60.1.164. Mol Pharmacol. 2001. PMID: 11408611 - Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100.
De Clercq E. De Clercq E. Mini Rev Med Chem. 2005 Sep;5(9):805-24. doi: 10.2174/1389557054867075. Mini Rev Med Chem. 2005. PMID: 16178723 Review. - Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists.
De Clercq E. De Clercq E. Mol Pharmacol. 2000 May;57(5):833-9. Mol Pharmacol. 2000. PMID: 10779364 Review.
Cited by
- Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.
Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Kioi M, et al. J Clin Invest. 2010 Mar;120(3):694-705. doi: 10.1172/JCI40283. Epub 2010 Feb 22. J Clin Invest. 2010. PMID: 20179352 Free PMC article. - Endothelial-immune crosstalk contributes to vasculopathy in nonalcoholic fatty liver disease.
Ng CY, Lee KL, Muthiah MD, Wu KX, Chioh FWJ, Tan K, Soon GST, Shabbir A, Loo WM, Low ZS, Chen Q, Tan NS, Ng HH, Dan YY, Cheung C. Ng CY, et al. EMBO Rep. 2022 Jun 7;23(6):e54271. doi: 10.15252/embr.202154271. Epub 2022 Apr 11. EMBO Rep. 2022. PMID: 35403791 Free PMC article. - Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.
Hübel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C, Galm O, Hartwig R, Heits F, Lordick F, Rösler W, Wehler D, Zander AR, Albert MH, Dressler S, Ebinger M, Frickhofen N, Hertenstein B, Kiehl M, Liebler S, von Lilienfeld-Toal M, Weidmann E, Weigelt C, Lange F, Kröger N. Hübel K, et al. Bone Marrow Transplant. 2011 Aug;46(8):1045-52. doi: 10.1038/bmt.2010.249. Epub 2010 Oct 25. Bone Marrow Transplant. 2011. PMID: 20972470 Clinical Trial. - An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors.
Herschhorn A, Finzi A, Jones DM, Courter JR, Sugawara A, Smith AB 3rd, Sodroski JG. Herschhorn A, et al. PLoS One. 2011;6(11):e26731. doi: 10.1371/journal.pone.0026731. Epub 2011 Nov 1. PLoS One. 2011. PMID: 22069466 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources